RET and thyroid cancer: Recently, quinazoline compounds, specific inhibitors of the RET thyrosine kinase pathway showed mild to significant anticancer efficacy in some tumor cell lines, including thyroid cancer, suggesting a possible future therapeutic potential in MEN2 [19].